Analysts expect Gilead Sciences, Inc. to report revenue of 8.82 B for Q4 26, against a range of 8.11 B to 9.53 B. The most recent reported quarter, Q3 26, came in at 8.30 B, a 13.5% beat against the 7.31 B consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 7.57 B | 6.67 B | 7.08 B | 7.77 B | 7.92 B | 6.96 B | 7.80 B | 8.30 B | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 7.34 B | 7.31 B | 7.50 B | 7.95 B | 7.85 B | 7.72 B | 7.86 B | 7.64 B | 9.53 B | 8.35 B | 8.92 B | 8.87 B | 9.01 B | 8.45 B | 8.73 B | 9.38 B | |||||||||
| Low Estimate | 6.39 B | 6.85 B | 7.05 B | 6.52 B | 6.56 B | 6.86 B | 6.48 B | 6.99 B | 8.11 B | 7.05 B | 7.76 B | 7.44 B | 7.76 B | 7.91 B | 7.45 B | 8.11 B | |||||||||
| Consensus Estimate | 6.86 B | 7.08 B | 7.28 B | 7.23 B | 7.20 B | 7.29 B | 7.17 B | 7.31 B | 8.82 B | 7.70 B | 8.34 B | 8.15 B | 8.39 B | 8.18 B | 8.09 B | 8.75 B |
Analysts expect Gilead Sciences, Inc. to report earnings per share of 1.46 for Q4 26, against a range of 1.33 to 1.59. The most recent reported quarter, Q3 26, came in at 2.55, a 12.3% beat against the 2.27 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.90 | 1.81 | 2.01 | 2.47 | 1.86 | 2.03 | -6.75 | 2.55 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 1.94 | 1.89 | 2.11 | 2.39 | 1.84 | 1.95 | -7.09 | 2.42 | 1.59 | 2.41 | 2.47 | 2.89 | 2.58 | 2.75 | 1.90 | 4.11 | |||||||||
| Low Estimate | 1.66 | 1.59 | 1.91 | 1.99 | 1.68 | 1.79 | -7.93 | 2.12 | 1.33 | 2.07 | 2.31 | 2.71 | 2.18 | 2.47 | 1.58 | 3.79 | |||||||||
| Consensus Estimate | 1.80 | 1.74 | 2.01 | 2.19 | 1.76 | 1.87 | -7.51 | 2.27 | 1.46 | 2.24 | 2.39 | 2.80 | 2.38 | 2.61 | 1.74 | 3.95 |
Pull Wall Street consensus for Gilead Sciences, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=GILD&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "GILD", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=GILD&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();